SinoMab Bioscience (3681 HK)

SinoMab Bioscience is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of monoclonal antibody-based therapeutics for immunological diseases. Its flagship product, SM03 (Suciraslimab), targets rheumatoid arthritis and other autoimmune conditions. The company was founded in 2001 and is headquartered in Hong Kong.